CTLA-4 primarily regulates T-cell activation at the priming stage in tumour-draining lymph nodes involving CD28-mediated T-cell co-stimulation, while PD-1 inhibition primarily occurs at the tumour site during the effector phase. The gene discussed is PDCD1; the disease is neoplasm.